Nearly all of Latin America was excluded from the deal, sparking concern the world is missing a critical opportunity to stop ...
A recent phase 3 trial found that twice-yearly injections of Lenacapavir reduce the risk of contracting HIV by 96%. | Drug ...
A new, long-acting injectable to prevent HIV infection could be a “game-changer” in ending the AIDS epidemic, if all who ...
Lenacapavir, an antiretroviral drug typically used to treat HIV infections, can also effectively prevent them, a phase 3 ...
A new HIV prevention method, Lenacapavir, administered as a twice-yearly injection, has demonstrated superior results ...
Tengrinews.kz - A revolutionary HIV drug has been created: clinical trials have shown that its twice-yearly injections are 96 ...
Scientists have developed Lenacapavir, a twice-yearly injection that cuts HIV infection risk by 96% in groundbreaking trials.
The twice-yearly HIV prevention shot developed by Gilead has shown impressive results in preventing infections among both men ...
We still have 1.3 million new infections a year, the majority of which occur in marginalised and vulnerable groups. But we ...